Enalapril ( DrugBank: Enalapril )


6 diseases
告示番号疾患名(ページ内リンク)臨床試験数
19ライソゾーム病1
46悪性関節リウマチ1
66IgA腎症3
113筋ジストロフィー2
210単心室症1
222一次性ネフローゼ症候群1

19. ライソゾーム病


臨床試験数 : 899 薬物数 : 684 - (DrugBank : 99) / 標的遺伝子数 : 51 - 標的パスウェイ数 : 182
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1NCT00446862
(ClinicalTrials.gov)
March 200711/3/2007The Fabrazyme® and Arbs and ACE Inhibitor Treatment (FAACET) StudyMulti-center, Open-label Study of the Safety and Efficacy of Control of Proteinuria With ACE Inhibitors and ARBS in Patients With Fabry Disease Who Are Receiving Fabrazyme®: The FAACET StudyFabry Disease;ProteinuriaDrug: enalapril and other angiotensin converting enzyme inhibitors; losartan and other angiotensin receptor blockersUniversity of Alabama at BirminghamNULLCompleted19 Years85 YearsBoth36N/AUnited States;Slovenia;Germany

46. 悪性関節リウマチ


臨床試験数 : 4,356 薬物数 : 2,567 - (DrugBank : 415) / 標的遺伝子数 : 192 - 標的パスウェイ数 : 228
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1NCT03667131
(ClinicalTrials.gov)
February 13, 201710/9/2018Enalapril Maleate on Arterial Stiffness in Rheumatoid Arthritis.Effect of Prophylactic Treatment With Enalapril Maleate on Arterial Stiffness in Rheumatoid Arthritis Patients.Rheumatoid ArthritisDrug: Enalapril Maleate;Drug: PlaceboUniversity of GuadalajaraNULLCompleted18 Years80 YearsFemale59Phase 2Mexico

66. IgA腎症


臨床試験数 : 275 薬物数 : 258 - (DrugBank : 82) / 標的遺伝子数 : 36 - 標的パスウェイ数 : 140
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1JPRN-C000000380
2003/04/0131/03/2006The renoprotective effects of ARB in patients with IgA nephropathy : multicenter,radomized trialThe renoprotective effects of ARB in patients with IgA nephropathy : multicenter,radomized trial - ARB and IgA nephropathy IgA nephropathyARB valsartan

ACE-I enalapril
ARB therapeutic society of IgA nephropathyNULLComplete: follow-up complete16years-old75years-oldMale and Female400Phase 4Japan
2NCT00006137
(ClinicalTrials.gov)
May 20003/8/2000Pilot Study of Enalapril and Renal Function in Patients With IgA NephropathyIGA GlomerulonephritisDrug: enalaprilNational Center for Research Resources (NCRR)Stanford UniversityCompleted13 Years60 YearsBoth43N/ANULL
3NCT00367562
(ClinicalTrials.gov)
January 199622/8/2006Inhibition of the Renin Angiotensin System Plus Corticosteroids for the Treatment of Proteinuria in IGA NephropathyPhase IV Open Label Uncontrolled Trial of the Dual Blockade of the Renin Angiotensin System With Enalapril Plus Valsartan Combined With Oral Methylprednisolone for the Treatment of Proteinuria in IGA NephropathyIGA NephropathyDrug: ENALAPRIL VALSARTAN METHYLPREDNISONEHospital BritanicoNULLCompleted21 Years70 YearsBoth20Phase 4Argentina

113. 筋ジストロフィー


臨床試験数 : 646 薬物数 : 471 - (DrugBank : 105) / 標的遺伝子数 : 59 - 標的パスウェイ数 : 170
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1NCT02432885
(ClinicalTrials.gov)
June 200924/3/2015Myocardial Fibrosis Progression in Duchenne and Becker Muscular Dystrophy - ACE Inhibitor Therapy TrialMyocardial Fibrosis Progression in Duchenne and Becker Muscular Dystrophy - Angiotensin-Converting-Enzyme (ACE) Inhibitor TherapyMyocardial Fibrosis;Muscular DystrophiesDrug: EnalaprilInCor Heart InstituteFederal University of Minas Gerais;University of Sao PauloCompleted6 YearsN/ABoth76Phase 3NULL
2EUCTR2009-009871-36-DE
(EUCTR)
06/08/2009Study within children with Duchenne Muscular DystrophyEffect and Safety of preventive Treatment with ACE-Inhibitor and Beta-Blocker on the onset of Left Ventricular Dysfunction in Duchenne Muscular Dystrophy - DMD-Kardio Therapeutic area: Diseases [C] - Musculoskeletal Diseases [C05]Trade Name: EnalHexal®, 5 mg
INN or Proposed INN: ENALAPRIL
Trade Name: EnaHexal®, 10mg
INN or Proposed INN: ENALAPRIL
Trade Name: MetoHEXAL® Succ ® 23,75 mg Retardtabletten
INN or Proposed INN: METOPROLOL SUCCINATE
Trade Name: MetoHEXAL® Succ ® 47,5 mg Retardtabletten
INN or Proposed INN: METOPROLOL SUCCINATE
Trade Name: MetoHEXAL® Succ ® 95 mg Retardtabletten
INN or Proposed INN: METOPROLOL SUCCINATE
Friedrich- Alexander- Universität Erlangen NürnbergNULLNot RecruitingFemale: no
Male: yes
Germany

210. 単心室症


臨床試験数 : 51 薬物数 : 53 - (DrugBank : 22) / 標的遺伝子数 : 32 - 標的パスウェイ数 : 67
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1NCT00113087
(ClinicalTrials.gov)
August 20033/6/2005Trial of Angiotensin Converting Enzyme Inhibition in Infants With Single Ventricle--Pediatric Heart NetworkTrial of ACE Inhibition in Infants With Single Ventricle (A Trial Conducted by the Pediatric Heart Network)Heart Defects, Congenital;Heart Failure, CongestiveDrug: Enalapril;Drug: PlaceboNational Heart, Lung, and Blood Institute (NHLBI)Pediatric Heart NetworkCompletedN/A45 DaysAll230Phase 3United States;Canada

222. 一次性ネフローゼ症候群


臨床試験数 : 310 薬物数 : 295 - (DrugBank : 117) / 標的遺伝子数 : 63 - 標的パスウェイ数 : 194
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1NCT04183101
(ClinicalTrials.gov)
October 1, 202014/11/2019Evaluation of a Renin Inhibitor, Aliskiren, Compared to Enalapril, in C3 GlomerulopathyPhase 2, Multicenter, Randomized, Open-label, Controlled, 2-arm Cross-over Study to Evaluate the Clinical Efficacy of a Renin Inhibitor, Aliskiren, Compared to an Angiotensin Converting Enzyme Inhibitor, Enalapril, in C3 GlomerulopathyC3 Glomerulopathy;Membranoproliferative Glomerulonephritis;Complement Abnormality;Dense Deposit Disease;C3 GlomerulonephritisDrug: Aliskiren;Drug: EnalaprilRegion SkaneNULLRecruiting6 YearsN/AAll30Phase 2Sweden